ALB and hepatocellular carcinoma: Studies conducted by Hickey et al. [76], Gui et al. [77], Kim et al. [78], Antkowiak et al. [79], Khalid et al. [80], Lee et al. [81], Zhong et al. [82], Ho et al. [83], and Chen et al. [84] confirmed that a high pre-treatment serum ALB–BIL grade was an independent factor which predicted worse OS in HCC patients receiving TACE or transarterial radioembolization (TARE).